TCMD Key Statistics, Chart & Performance
The current stock price of TCMD is 30.5 USD. In the past month the price increased by 9.28%. In the past year, price increased by 77.02%.
TCMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.61 | 222.19B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.86 | 210.17B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.15 | 144.97B | ||
| SYK | STRYKER CORP | 27.82 | 140.11B | ||
| BDX | BECTON DICKINSON AND CO | 14.24 | 58.61B | ||
| IDXX | IDEXX LABORATORIES INC | 56.05 | 56.44B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.4 | 49.82B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.9 | 39.51B | ||
| RMD | RESMED INC | 25.17 | 36.37B | ||
| DXCM | DEXCOM INC | 37.58 | 27.26B | ||
| PODD | INSULET CORP | 64.41 | 20.71B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.71 | 18.78B |
Related stock screener links
About TCMD
Company Profile
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,037 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The company also offers Kylee, a free mobile application that helps patients learn about lymphedema.
Company Info
TACTILE SYSTEMS TECHNOLOGY I
3701 Wayzata Blvd, Suite 300
Minneapolis MINNESOTA 55416 US
CEO: Daniel L. Reuvers
Employees: 1037
Phone: 18333822845
TACTILE SYSTEMS TECHNOLOGY I / TCMD FAQ
Can you describe the business of TACTILE SYSTEMS TECHNOLOGY I?
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,037 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The company also offers Kylee, a free mobile application that helps patients learn about lymphedema.
What is the stock price of TACTILE SYSTEMS TECHNOLOGY I today?
The current stock price of TCMD is 30.5 USD. The price increased by 1.23% in the last trading session.
Does TCMD stock pay dividends?
TCMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of TCMD stock?
TCMD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of TCMD stock?
TACTILE SYSTEMS TECHNOLOGY I (TCMD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Is TACTILE SYSTEMS TECHNOLOGY I (TCMD) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TCMD.
TCMD Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TCMD. When comparing the yearly performance of all stocks, TCMD is one of the better performing stocks in the market, outperforming 97.08% of all stocks.
TCMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TCMD. While TCMD has a great health rating, its profitability is only average at the moment.
TCMD Financial Highlights
Over the last trailing twelve months TCMD reported a non-GAAP Earnings per Share(EPS) of 0.77. The EPS increased by 16.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.83% | ||
| ROA | 7.01% | ||
| ROE | 8.86% | ||
| Debt/Equity | 0 |
TCMD Forecast & Estimates
11 analysts have analysed TCMD and the average price target is 24.48 USD. This implies a price decrease of -19.74% is expected in the next year compared to the current price of 30.5.
For the next year, analysts expect an EPS growth of 14.64% and a revenue growth 9.19% for TCMD